Wedbush Equities Analysts Raise Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at Wedbush increased their Q3 2025 earnings per share estimates for shares of Stoke Therapeutics in a research note issued on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.57) per share for the quarter, up from their prior forecast of ($0.58). Wedbush has a “Outperform” rating and a $22.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ FY2025 earnings at $0.35 EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.58) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($2.12) EPS and FY2029 earnings at $0.30 EPS.

Several other brokerages also recently commented on STOK. Cantor Fitzgerald raised Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They issued a “buy” rating and a $30.00 price objective on the stock. Chardan Capital reissued a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, HC Wainwright decreased their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $25.17.

Stoke Therapeutics Trading Up 6.1%

Shares of STOK opened at $18.21 on Friday. The company has a market capitalization of $997.91 million, a PE ratio of 21.42 and a beta of 1.15. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $18.45. The stock’s 50-day moving average price is $12.55 and its two-hundred day moving average price is $10.16.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.

Insider Buying and Selling

In other news, General Counsel Jonathan Allan sold 13,712 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $15.00, for a total value of $205,680.00. Following the transaction, the general counsel owned 19,631 shares in the company, valued at $294,465. The trade was a 41.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 4,504 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the completion of the transaction, the insider owned 16,775 shares in the company, valued at $215,055.50. The trade was a 21.17% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,432 shares of company stock valued at $345,775 over the last three months. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC boosted its stake in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after buying an additional 5,084 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. AlphaQuest LLC purchased a new position in Stoke Therapeutics in the first quarter valued at approximately $72,000. Finally, US Bancorp DE lifted its stake in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after purchasing an additional 11,108 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.